Blog
RSS FeedPosted by Michael Wonder on 12 Sep 2023
Incorporating added therapeutic benefit and domestic reference pricing into Medicare payment for expensive Part B drugs
10 September 2023 - A retrospective analysis using a 20% nationally representative sample of 2015 to 2019 traditional Medicare Part B ...
Posted by Michael Wonder on 08 Sep 2023
Protecting Medicare’s discretion to say no to unproven therapies
8 September 2023 - Medicare, the largest health care payer in the nation, is also the single biggest source of revenue ...
Posted by Michael Wonder on 08 Sep 2023
Review of cancer related surrogate outcomes used for PBAC decision-making
8 September 2023 - Surrogate outcome measures have an increasingly important role in cancer medicine research providing evidence to support ...
Posted by Michael Wonder on 29 Aug 2023
Australia knocks back application for diabetes drug that could overshadow Ozempic
29 August 2023 - Australia has knocked back an application to subsidise the diabetes drug Mounjaro but the manufacturer still wants ...
Posted by Michael Wonder on 14 Aug 2023
In the case of a devastating disease, the FDA weighs an experimental drug’s muddled data and a desperate need
14 August 2023 - Emma Albee knows the experimental drug she takes is not a cure. It won’t allow her ...
Posted by Michael Wonder on 30 Jul 2023
PHARMAC’s funding model creating an ‘ethical dilemma’ - specialist
29 July 2023 - The New Zealand Breast Cancer Foundation is renewing calls for PHARMAC to fund Keytruda for the ...
Posted by Michael Wonder on 29 Jul 2023
Statutory authority for Medicare coverage decisions - CMS is an independent federal agency
28 July 2023 - It is time for the public to recognize and strongly support the authority of the US Centers ...
Posted by Michael Wonder on 13 Jun 2023
Pilot expert committee to support decision-making across the drug life cycle
8 June 2023 - CADTH, Canada’s drug and health technology agency, announces the creation and inaugural membership of a new ...
Posted by Michael Wonder on 29 May 2023
A review of HTA guidelines on societal and novel value elements
25 May 2023 - Health technology assessment organisations vary in terms of how they conduct assessments. ...
Posted by Michael Wonder on 23 May 2023
Health Canada’s position on the CADTH guidance for reporting RWE to support decision-making
18 May 2023 - Canada’s CADTH collaborated with Health Canada and other stakeholders to develop the guidance for reporting real world ...
Posted by Michael Wonder on 29 Apr 2023
Prioritising patients in negotiations over drug pricing
14 April 2023 - Overpaying for medicines diverts funds away from other treatments and services. ...
Posted by Michael Wonder on 30 Mar 2023
Clarity around PHARMAC’s priority lists
30 March 2023 - PHARMAC released its first Clarity Report, containing the latest information about medicines, vaccines, and related products ...
Posted by Michael Wonder on 10 Mar 2023
Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices.
10 March 2023 - By law, Medicare will have to take a medication’s efficacy and its research and development costs ...
Posted by Michael Wonder on 05 Mar 2023
Our progress in the funding of medicines for rare disorders
3 March 2023 - PHARMAC will hear from people affected by rare disorders in its upcoming Rare Disorders Advisory Committee meeting ...
Posted by Michael Wonder on 08 Feb 2023
Speeding up access to new medicines in Scotland: abbreviated process
8 February 2023 - A process brought in to streamline decision-making around access to new medicines in NHSScotland during the ...